Company profile MLTX
After 39 days of this quarter the interest is at 51.0. Based on that we can calculate that during remaining 52 days it will total up to 119.0. MoonLake Immunotherapeutics expected interest is significantly higher compared to same quarter last year (+48.8%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 38 | 138 263.2% QoQ | 76 -44.9% QoQ | 100 31.6% QoQ |
| 2020 | 178 368.4% YoY 78.0% QoQ | 52 -62.3% YoY -70.8% QoQ | 95 25.0% YoY 82.7% QoQ | 75 -25.0% YoY -21.1% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 53 1.9% YoY inf% QoQ | 53 -44.2% YoY 0.0% QoQ | 32 -57.3% YoY -39.6% QoQ |
| 2022 | 45 inf% YoY 40.6% QoQ | 47 -11.3% YoY 4.4% QoQ | 121 128.3% YoY 157.4% QoQ | 26 -18.8% YoY -78.5% QoQ |
| 2023 | 80 77.8% YoY 207.7% QoQ | 271 476.6% YoY 238.8% QoQ | 317 162.0% YoY 17.0% QoQ | 140 438.5% YoY -55.8% QoQ |
| 2024 | 51 -36.2% YoY -63.6% QoQ | - | - | - |
The average 5 years interest of MoonLake Immunotherapeutics was 7.62 per week. The last year interest of MoonLake Immunotherapeutics compared to the last 5 years has changed by 111.68%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 93.64%.
After 39 days of this quarter the interest is at 64.0. Based on that we can calculate that during remaining 52 days it will total up to 149.0. Sonelokimab expected interest is significantly higher compared to same quarter last year (+41.9%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 25 inf% QoQ | 91 264.0% QoQ | 77 -15.4% QoQ |
| 2020 | 52 inf% YoY -32.5% QoQ | 77 208.0% YoY 48.1% QoQ | 0 -100.0% YoY -100.0% QoQ | 106 37.7% YoY inf% QoQ |
| 2021 | 93 78.8% YoY -12.3% QoQ | 147 90.9% YoY 58.1% QoQ | 145 inf% YoY -1.4% QoQ | 127 19.8% YoY -12.4% QoQ |
| 2022 | 105 12.9% YoY -17.3% QoQ | 105 -28.6% YoY 0.0% QoQ | 72 -50.3% YoY -31.4% QoQ | 84 -33.9% YoY 16.7% QoQ |
| 2023 | 105 0.0% YoY 25.0% QoQ | 55 -47.6% YoY -47.6% QoQ | 77 6.9% YoY 40.0% QoQ | 110 31.0% YoY 42.9% QoQ |
| 2024 | 64 -39.0% YoY -41.8% QoQ | - | - | - |
The average 5 years interest of Sonelokimab was 6.58 per week. The last year interest of Sonelokimab compared to the last 5 years has changed by 2.89%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 82.48%.
After 34 days of this quarter the interest is at 177.0. Based on that we can calculate that during remaining 58 days it will total up to 479.0. inflammation diseases treatment expected interest is significantly higher compared to previous quarter (+69.3%) and same quarter last year (+98.8%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 72 |
| 2019 | 108 50.0% QoQ | 39 -63.9% QoQ | 68 74.4% QoQ | 115 59.7% YoY 69.1% QoQ |
| 2020 | 61 -43.5% YoY -47.0% QoQ | 138 253.8% YoY 126.2% QoQ | 128 88.2% YoY -7.2% QoQ | 132 14.8% YoY 3.1% QoQ |
| 2021 | 130 113.1% YoY -1.5% QoQ | 128 -7.2% YoY -1.5% QoQ | 126 -1.6% YoY -1.6% QoQ | 75 -43.2% YoY -40.5% QoQ |
| 2022 | 35 -73.1% YoY -53.3% QoQ | 186 45.3% YoY 431.4% QoQ | 108 -14.3% YoY -41.9% QoQ | 241 221.3% YoY 123.1% QoQ |
| 2023 | 205 485.7% YoY -14.9% QoQ | 196 5.4% YoY -4.4% QoQ | 283 162.0% YoY 44.4% QoQ | 177 -26.6% YoY -37.5% QoQ |
The average 5 years interest of inflammation diseases treatment was 10.58 per week. The last year interest of inflammation diseases treatment compared to the last 5 years has changed by 76.28%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 216.1%.
There is not enough data for clinical-stage biopharmaceutical company to provide analysis
There is not enough data for clinical-stage biopharmaceutical company to provide correlation calculation
There is not enough data for clinical-stage biopharmaceutical company to provide analysis
After 39 days of this quarter the interest is at 339.0. Based on that we can calculate that during remaining 52 days it will total up to 791.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 275 | 447 62.5% QoQ | 571 27.7% QoQ | 558 -2.3% QoQ |
| 2020 | 470 70.9% YoY -15.8% QoQ | 557 24.6% YoY 18.5% QoQ | 701 22.8% YoY 25.9% QoQ | 736 31.9% YoY 5.0% QoQ |
| 2021 | 673 43.2% YoY -8.6% QoQ | 777 39.5% YoY 15.5% QoQ | 801 14.3% YoY 3.1% QoQ | 687 -6.7% YoY -14.2% QoQ |
| 2022 | 814 21.0% YoY 18.5% QoQ | 830 6.8% YoY 2.0% QoQ | 868 8.4% YoY 4.6% QoQ | 755 9.9% YoY -13.0% QoQ |
| 2023 | 691 -15.1% YoY -8.5% QoQ | 775 -6.6% YoY 12.2% QoQ | 911 5.0% YoY 17.5% QoQ | 815 7.9% YoY -10.5% QoQ |
| 2024 | 339 -50.9% YoY -58.4% QoQ | - | - | - |
The average 5 years interest of hidradenitis suppurativa treatment was 53.84 per week. The last year interest of hidradenitis suppurativa treatment compared to the last 5 years has changed by 15.9%. The interest for hidradenitis suppurativa treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 58.82%.
After 39 days of this quarter the interest is at 327.0. Based on that we can calculate that during remaining 52 days it will total up to 763.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 441 | 751 70.3% QoQ | 618 -17.7% QoQ | 678 9.7% QoQ |
| 2020 | 706 60.1% YoY 4.1% QoQ | 675 -10.1% YoY -4.4% QoQ | 737 19.3% YoY 9.2% QoQ | 818 20.6% YoY 11.0% QoQ |
| 2021 | 820 16.1% YoY 0.2% QoQ | 907 34.4% YoY 10.6% QoQ | 668 -9.4% YoY -26.4% QoQ | 637 -22.1% YoY -4.6% QoQ |
| 2022 | 799 -2.6% YoY 25.4% QoQ | 696 -23.3% YoY -12.9% QoQ | 774 15.9% YoY 11.2% QoQ | 680 6.8% YoY -12.1% QoQ |
| 2023 | 865 8.3% YoY 27.2% QoQ | 735 5.6% YoY -15.0% QoQ | 778 0.5% YoY 5.9% QoQ | 787 15.7% YoY 1.2% QoQ |
| 2024 | 327 -62.2% YoY -58.4% QoQ | - | - | - |
The average 5 years interest of psoriatic arthritis treatment was 57.08 per week. The last year interest of psoriatic arthritis treatment compared to the last 5 years has changed by 4.03%. The interest for psoriatic arthritis treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 10.43%.
After 39 days of this quarter the interest is at 145.0. Based on that we can calculate that during remaining 52 days it will total up to 338.0. ankylosing spondylitis treatment expected interest is significantly lower compared to previous quarter (-44.2%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 309 | 495 60.2% QoQ | 466 -5.9% QoQ | 431 -7.5% QoQ |
| 2020 | 493 59.5% YoY 14.4% QoQ | 457 -7.7% YoY -7.3% QoQ | 531 13.9% YoY 16.2% QoQ | 416 -3.5% YoY -21.7% QoQ |
| 2021 | 459 -6.9% YoY 10.3% QoQ | 588 28.7% YoY 28.1% QoQ | 590 11.1% YoY 0.3% QoQ | 463 11.3% YoY -21.5% QoQ |
| 2022 | 710 54.7% YoY 53.3% QoQ | 683 16.2% YoY -3.8% QoQ | 664 12.5% YoY -2.8% QoQ | 683 47.5% YoY 2.9% QoQ |
| 2023 | 530 -25.4% YoY -22.4% QoQ | 618 -9.5% YoY 16.6% QoQ | 555 -16.4% YoY -10.2% QoQ | 606 -11.3% YoY 9.2% QoQ |
| 2024 | 145 -72.6% YoY -76.1% QoQ | - | - | - |
The average 5 years interest of ankylosing spondylitis treatment was 41.73 per week. The last year interest of ankylosing spondylitis treatment compared to the last 5 years has changed by 2.85%. The interest for ankylosing spondylitis treatment is seasonal. The last year interest is quite higher compared to 5 years ago. It has increased by 15.63%.
There is not enough data for axial spondyloarthritis treatment to provide analysis
There is not enough data for axial spondyloarthritis treatment to provide correlation calculation
There is not enough data for axial spondyloarthritis treatment to provide analysis
There is not enough data for MoonLake Immunotherapeutics headquarters to provide analysis
There is not enough data for MoonLake Immunotherapeutics headquarters to provide correlation calculation
There is not enough data for MoonLake Immunotherapeutics headquarters to provide analysis
There is not enough data for MoonLake Immunotherapeutics stock -company to provide analysis
There is not enough data for MoonLake Immunotherapeutics stock -company to provide correlation calculation
There is not enough data for MoonLake Immunotherapeutics stock -company to provide analysis